NCT05000346View on ClinicalTrials.gov

Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

December 21, 2022

Study Completion Date

December 21, 2022

Conditions
Covid19
Interventions
DRUG

Drug, inhalation

Solution administered by inhalation

Trial Locations (1)

4000

CHU Liege, Liège

Sponsors
All Listed Sponsors
lead

Aquilon Pharmaceuticals S.A.

INDUSTRY